Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area
HIV 流行地区广泛耐药结核病治疗反应和耐药性的生物标志物
基本信息
- 批准号:9088299
- 负责人:
- 金额:$ 13.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-11 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeAntimycobacterial AgentsApplications GrantsAreaBacteriophagesBioethicsBiological AssayBiological MarkersBiometryCase Fatality RatesCharacteristicsClinicalClinical TrialsCollaborationsColony-forming unitsCommunitiesComplexDataDevelopmentDevelopment PlansDiagnosisDiagnosticDrug resistanceDrug resistance in tuberculosisEarly treatmentEngineeringEpidemiologistExtreme drug resistant tuberculosisFluorescenceFoundationsFundingGenerationsGenus MycobacteriumGoalsGray unit of radiation doseHIVHIV drug resistanceHIV/TBHourIn VitroIncidenceK-Series Research Career ProgramsLaboratoriesLightManuscriptsMeasuresMedicineMentorsMicrobiologyMolecularMycobacteriophagesMycobacterium tuberculosisOutcomePatientsPharmaceutical PreparationsPopulationPredispositionProcessProspective StudiesReactionRegimenReporterReporter GenesResearchResearch InfrastructureResearch InstituteResearch PersonnelResearch ProposalsResistanceRoleSamplingScientistSignal TransductionSolidSouth AfricaSputumSurrogate MarkersSystemTestingTimeTrainingTreatment outcomeTuberculosisValidationVirusWorkbasecareercareer developmentclinical biomarkersclinical decision-makingclinical practiceco-infectioncollegecomparative efficacyexperienceextensive drug resistanceglobal healthimprovedinnovationlaboratory experiencelecturesmolecular markernovelnovel therapeuticsprogramspromoterresearch and developmentresistant straintransmission processtreatment responsetuberculosis treatment
项目摘要
DESCRIPTION (provided by applicant): This proposal describes a career development plan and research proposal for Dr. Max O'Donnell, a pulmonologist at Albert Einstein College of Medicine. Working with collaborators and mentors at Einstein and in South Africa, Dr. O'Donnell is establishing himself as a translational investigator in drug-resistant tuberculosis (TB) and HIV
research. Nowhere has drug-resistant TB generated more alarm than in South Africa, where synergies between endemic TB and HIV have caused 'explosive' increases in TB incidence and case-fatality rates. The most resistant form of TB, extensively drug resistant tuberculosis (XDR-TB), is increasingly prevalent in South Africa. An important obstacle to improving survival for XDR-TB is lack of a rapid, biomarker to serve as a surrogate outcome in clinical trials and guide clinician's by measuring treatment response. Fluoromycobacteriophage (FMP) assays use genetically modified mycobacteria-specific viruses to quantify viable M tuberculosis (Mtb) using a fluorescence reporter system. Utilizing a novel FMP assay with superior test characteristics, Dr. O'Donnell proposes to measure decrease in Mtb in XDR-TB patients' sputum as a biomarker for treatment response (Aim 1). Among XDR-TB patients who fail to respond to treatment Dr. O'Donnell proposes to use the same assay to rapidly diagnose emergent second-line drug resistance (Aim 2). This research component of this proposal is a result of an ongoing funded collaboration between researchers at Albert Einstein College of Medicine with researchers at the KwaZulu-Natal Research Institute for Research in Tuberculosis and HIV/AIDS (K-RITH), and the Centre for AIDS Programme of Research in South Africa (CAPRISA). The training component of this proposal involves developing the applicant as a TB molecular epidemiologist including training in the mentor's laboratory, coursework, seminars, lectures, and specific training in drug-resistant TB microbiology. Unique features include co-mentoring from a renowned TB basic scientist, TB epidemiologist, and translational researcher with additional support from career development committee with extensive TB and career development experience. This is an innovative approach with the potential to make substantial impact in our ability to rationally manage drug-resistant tuberculosis, rapidly evaluate the comparative efficacy
of different drug regimens, and rapidly diagnose emergent drug-resistance among TB patients on treatment. This research will form the basis for a prospective study of the application of clinical biomarkers for treatment outcome in drug-resistant tuberculosis that will be proposed in an R01 grant application before the end of the K award.
描述(由申请人提供):本计划书描述了爱因斯坦医学院肺科医生Max O'Donnell博士的职业发展计划和研究计划。O'Donnell博士与爱因斯坦大学和南非的合作者和导师合作,正在确立自己在耐药结核病和艾滋病毒方面的转化研究员地位
项目成果
期刊论文数量(17)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.
- DOI:10.1093/jac/dku235
- 发表时间:2014-11
- 期刊:
- 影响因子:0
- 作者:N. Padayatchi;M. Gopal;R. Naidoo;L. Werner;K. Naidoo;I. Master;M. O’Donnell
- 通讯作者:N. Padayatchi;M. Gopal;R. Naidoo;L. Werner;K. Naidoo;I. Master;M. O’Donnell
Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.
- DOI:10.1097/qai.0000000000000650
- 发表时间:2015-08-15
- 期刊:
- 影响因子:0
- 作者:OʼDonnell MR;Pillay M;Pillay M;Werner L;Master I;Wolf A;Mathema B;Coovadia YM;Mlisana K;Horsburgh CR;Padayatchi N
- 通讯作者:Padayatchi N
Turning the tide against tuberculosis.
扭转结核病的颓势。
- DOI:10.1016/j.ijid.2017.01.012
- 发表时间:2017
- 期刊:
- 影响因子:0
- 作者:Padayatchi,Nesri;Naidu,Naressa;Friedland,Gerald;Naidoo,Kasavan;Conradie,Francesca;Naidoo,Kogieleum;O'Donnell,MaxRoe
- 通讯作者:O'Donnell,MaxRoe
Emergence, Epidemiology, and Transmission Dynamics of 2009 Pandemic A/H1N1 Influenza in Kampala, Uganda, 2009-2015.
2009-2015 年乌干达坎帕拉 2009 年甲型 H1N1 流感大流行的出现、流行病学和传播动态。
- DOI:10.4269/ajtmh.17-0524
- 发表时间:2018
- 期刊:
- 影响因子:0
- 作者:Cummings,MatthewJ;Bakamutumaho,Barnabas;Yang,Wan;Wamala,JosephF;Kayiwa,John;Owor,Nicholas;Namagambo,Barbara;Byaruhanga,Timothy;Wolf,Allison;Lutwama,JuliusJ;Shaman,Jeffrey;O'Donnell,MaxR
- 通讯作者:O'Donnell,MaxR
Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa.
- DOI:10.1097/qai.0000000000001833
- 发表时间:2018-12-01
- 期刊:
- 影响因子:0
- 作者:Yuengling KA;Padayatchi N;Wolf A;Mathema B;Brown T;Horsburgh CR;OʼDonnell MR
- 通讯作者:OʼDonnell MR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Max O'Donnell其他文献
Max O'Donnell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Max O'Donnell', 18)}}的其他基金
Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage
使用下一代纳米荧光素酶报告噬菌体快速表型检测复杂和突发的结核病耐药性
- 批准号:
10662977 - 财政年份:2023
- 资助金额:
$ 13.42万 - 项目类别:
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
对移动医疗和传统依从性支持干预措施进行适应性评估,以优化南非耐药结核病和艾滋病毒新治疗方案的结果
- 批准号:
10589840 - 财政年份:2022
- 资助金额:
$ 13.42万 - 项目类别:
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
对移动医疗和传统依从性支持干预措施进行适应性评估,以优化南非耐药结核病和艾滋病毒新治疗方案的结果
- 批准号:
10484620 - 财政年份:2022
- 资助金额:
$ 13.42万 - 项目类别:
Targeted next-generation sequencing to enhance detection and genomic characterization of Mycobacterium tuberculosis and high-impact bacterial pathogens among HIV-infected adults with sepsis in Uganda
靶向下一代测序可增强乌干达感染艾滋病毒的脓毒症成人中结核分枝杆菌和高影响细菌病原体的检测和基因组特征
- 批准号:
10116263 - 财政年份:2020
- 资助金额:
$ 13.42万 - 项目类别:
Targeted next-generation sequencing to enhance detection and genomic characterization of Mycobacterium tuberculosis and high-impact bacterial pathogens among HIV-infected adults with sepsis in Uganda
靶向下一代测序可增强乌干达感染艾滋病毒的脓毒症成人中结核分枝杆菌和高影响细菌病原体的检测和基因组特征
- 批准号:
9927189 - 财政年份:2020
- 资助金额:
$ 13.42万 - 项目类别:
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa
促进南非耐药结核病/艾滋病毒护理连续体的参与
- 批准号:
9254436 - 财政年份:2016
- 资助金额:
$ 13.42万 - 项目类别:
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa
促进南非耐药结核病/艾滋病毒护理连续体的参与
- 批准号:
9894715 - 财政年份:2016
- 资助金额:
$ 13.42万 - 项目类别:
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa
促进南非耐药结核病/艾滋病毒护理连续体的参与
- 批准号:
9117193 - 财政年份:2016
- 资助金额:
$ 13.42万 - 项目类别:
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area
HIV 流行地区广泛耐药结核病治疗反应和耐药性的生物标志物
- 批准号:
8410973 - 财政年份:2012
- 资助金额:
$ 13.42万 - 项目类别:
Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic Area
HIV 流行地区广泛耐药结核病治疗反应和耐药性的生物标志物
- 批准号:
8508846 - 财政年份:2012
- 资助金额:
$ 13.42万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 13.42万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 13.42万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 13.42万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 13.42万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 13.42万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 13.42万 - 项目类别:
Studies on cofactors for development of acquired immunodeficiency syndrome in feline immunodeficiency virus infection.
猫免疫缺陷病毒感染后获得性免疫缺陷综合征发生的辅助因子研究。
- 批准号:
03660315 - 财政年份:1991
- 资助金额:
$ 13.42万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 13.42万 - 项目类别: